Search results | monoclonal antibody

Reports

Cancer Monoclonal Antibody Partnering Terms and Agreements

The Cancer Monoclonal Antibody Partnering Agreements report provides an understanding and access to the cancer monoclonal antibody partnering deals and agreements entered into by the worlds leading healthcare companies

Monoclonal Antibodies Partnering Terms and Agreements

The report provides a detailed understanding and analysis of how and why companies enter monoclonal antibody partnering deals.

Antibody Partnering Terms & Agreements

The Antibody Partnering Terms and Agreements report provides comprehensive understanding and unprecedented access to the antibody partnering deals and agreements entered into by the worlds leading healthcare companies

Cancer Diagnostics Partnering Terms and Agreements

The Cancer Diagnostics Partnering Agreements report provides an understanding and access to the cancer diagnostics partnering deals and agreements entered into by the worlds leading healthcare companies.   Trends in cancer diagnostics partnering deals Disclosed headlines, upfronts, milestones and royalties by stage of development Cancer diagnostics partnering contract documents Top cancer diagnostics deals by value   The more »

Insights

Industry analysis: Cancer monoclonal antibody partnering on the rise

Monoclonal antibodies are developed to be very selective in targeting cells. This is why they have come to be an indispensable research tool in cancer treatment being able to specifically target tumor cells.

Market research analysis: Monoclonal antibody partnering

A recent market research analysis of monoclonal antibody partnering has shown a high interest in partnering deals involving monoclonal antibody technology in the past few years

Seattle Genetics: Empowering monoclonal antibodies

Seattle Genetics is a biotech company developing and commercializing antibody-based therapeutics to improve the lives of people living with cancer.

Antibody: recent life science partnering trends

Antibodies are the subject of numerous partnering deals every year, here we provide a review of recent partnering trends activity.

Antibody-drug conjugates

Antibody-drug conjugates (ADCs) are a new type of targeted therapy, used for example for cancer

Monoclonal antibodies

Monoclonal antibodies (mAb or moAb) are monospecific antibodies that are the same because they are made…

Antibody

An antibody, also known as an immunoglobulin, is a large Y-shaped protein produced by …..

PDL Biopharma: Capitalizing on the humanization of monoclonal antibodies

PDL Biopharma based in Nevada manages patents associated with its humanized monoclonal antibodies technology.   

MAb

Monoclonal antibody

AstraZeneca and Pfizer in the news for another possible m&a bid

AstraZeneca stock rose two percent to £45.67 pounds yesterday after the Swedish newspaper Dagens Industry suggested another possible Pfizer m&a  bid. AstraZeneca stocks have risen 9.5% in the last week, following a stream of good news regarding its pipeline and takeover bids by Pfizer.

Events

Development agreement for human regenerative therapy with induced pluripotent stem cells

Catalent Pharma Solutions announced an agreement with the Center for iPS Cell Research and Application at Kyoto University in Japan to make a major advancement toward one of the first regenerative human therapies with induced pluripotent stem (iPS) cells applicable to humans.

Deals

Merck big pharma deals Xencor for monoclonal antibody licensing agreement

Xencor enters pharma deals with Merck for the licensing of Xencor’s Fc engineering patents for a therapeutic monoclonal antibody to the big pharma company.

Morphotek in licensing deal with Centocor Ortho Biotech for exclusive development and commercialization fights for therapeutic monoclonal antibody

Morphotek has been granted an exclusive worldwide license for the development, manufacture and sale of the antibody. Financial terms were not disclosed. Preclinical studies, conducted by Centocor Ortho Biotech, have shown that the relevant antigen is over-expressed in many solid tumors.

Celgene and Open Monoclonal Tech in OmniAb alliance

Open Monoclonal Technology announced license that provides Celgene with unlimited access to OMT’s proprietary OmniRat, OmniMouse and OmniFlic platforms for generation of human antibody therapeutics

Sanofi and Boehringer Ingelheim in antibody manufacturing pact

Boehringer Ingelheim and Sanofi enter into an alliance to extend Sanofi’s manufacturing capacity network for therapeutic monoclonal antibodies

Licensing agreement for monoclonal antibodies

Visterra has secured an exclusive patent license from Massachusetts Institute of Technology to a family of early-stage monoclonal antibodies that target dengue virus.

Bayer pharma partners Seattle Genetics for collaboration on antibody-drug conjugate

Seattle Genetics has entered into a new antibody-drug conjugate collaboration with Bayer HealthCare, new pharma partners.

Boehringer Ingelheim big pharma deals Athera Biotech for novel cardiovascular antibody option agreement

Athera Biotechnologies has entered into pharma deals involving an option agreement with Boehringer Ingelheim on a novel preclinical antibody program.

Pfizer signs a pharma licensing deal with Open Monoclonal Technology

Pfizer, the world’s largest pharmaceutical company collaborated with Open Monoclonal Technology by signing a  pharma licensing agreement with the latter to use OMT’s OmniRat for antibody research and development

Arrowhead in new antibody evaluation pharma deals with big pharma Merck

Arrowhead Research Corporation announced signing of new pharma deals with Merck, through a subsidiary, to undertake an evaluation of a novel proprietary therapeutic monoclonal antibody candidate derived from Arrowhead’s human-derived peptide targeting and discovery program.

ImmunoGen announces antibody-drug conjugate collaboration with Eli Lilly, worth up to $200 million

ImmunoGen enters collaboration agreement with Eli Lilly and Company. Lilly will pay an upfront fee of $20 million for rights to take a limited number of exclusive licenses to use ImmunoGen’s maytansinoid Targeted Antibody Payload (TAP) technology with Lilly monoclonal antibodies to develop novel antibody-drug conjugate (ADC) anticancer therapeutics.